Emerging Opportunities and Challenges in Cancer Immunotherapy.
作者： Theresa L. Whiteside , Sandra Demaria , Maria E. Rodriguez-Ruiz , Hassane M. Zarour , Ignacio Melero
DOI: 10.1158/1078-0432.CCR-16-0049
关键词:
摘要: … for cancer immunotherapy. Immune cells infiltrating the TME are instructed to preferentially adopt the functional phenotypes and activities that support tumor progression. The instructive …
aacrjournals.org
sci-hub.se 参考文章(135)
Katherine H. Parker, Daniel W. Beury, Suzanne Ostrand-Rosenberg, Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Advances in Cancer Research. ,vol. 128, pp. 95- 139 ,(2015) , 10.1016/BS.ACR.2015.04.002
Claire Vanpouille-Box, Karsten A. Pilones, Erik Wennerberg, Silvia C. Formenti, Sandra Demaria, In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine. ,vol. 33, pp. 7415- 7422 ,(2015) , 10.1016/J.VACCINE.2015.05.105
Deepali V. Sawant, Kristia Hamilton, Dario A.A. Vignali, Interleukin-35: Expanding Its Job Profile. Journal of Interferon and Cytokine Research. ,vol. 35, pp. 499- 512 ,(2015) , 10.1089/JIR.2015.0015
Patrick J. Schuler, Bastian Schilling, Malgorzata Harasymczuk, Thomas K. Hoffmann, Jonas Johnson, Stephan Lang, Theresa L. Whiteside, Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. European Journal of Immunology. ,vol. 42, pp. 1876- 1885 ,(2012) , 10.1002/EJI.201142347
Stefani Spranger, Riyue Bao, Thomas F. Gajewski, Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity Nature. ,vol. 523, pp. 231- 235 ,(2015) , 10.1038/NATURE14404
Hatem H. Soliman, Erica Jackson, Tony Neuger, E. Claire Dees, R. Donald Harvey, Hyo Han, Roohi Ismail-Khan, Susan Minton, Nicholas N. Vahanian, Charles Link, Daniel M. Sullivan, Scott Antonia, A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors Oncotarget. ,vol. 5, pp. 8136- 8146 ,(2014) , 10.18632/ONCOTARGET.2357
Daniel J. Campbell, Control of Regulatory T Cell Migration, Function, and Homeostasis. Journal of Immunology. ,vol. 195, pp. 2507- 2513 ,(2015) , 10.4049/JIMMUNOL.1500801
Ignacio Melero, David M. Berman, M. Angela Aznar, Alan J. Korman, José Luis Pérez Gracia, John Haanen, Evolving synergistic combinations of targeted immunotherapies to combat cancer Nature Reviews Cancer. ,vol. 15, pp. 457- 472 ,(2015) , 10.1038/NRC3973
Alfred L. Garfall, Marcela V. Maus, Wei-Ting Hwang, Simon F. Lacey, Yolanda D. Mahnke, J. Joseph Melenhorst, Zhaohui Zheng, Dan T. Vogl, Adam D. Cohen, Brendan M. Weiss, Karen Dengel, Naseem D.S. Kerr, Adam Bagg, Bruce L. Levine, Carl H. June, Edward A. Stadtmauer, Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma The New England Journal of Medicine. ,vol. 373, pp. 1040- 1047 ,(2015) , 10.1056/NEJMOA1504542
Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F Stephen Hodi, Jacob Schachter, Anna C Pavlick, Karl D Lewis, Lee D Cranmer, Christian U Blank, Steven J O'Day, Paolo A Ascierto, April K S Salama, Kim A Margolin, Carmen Loquai, Thomas K Eigentler, Tara C Gangadhar, Matteo S Carlino, Sanjiv S Agarwala, Stergios J Moschos, Jeffrey A Sosman, Simone M Goldinger, Ronnie Shapira-Frommer, Rene Gonzalez, John M Kirkwood, Jedd D Wolchok, Alexander Eggermont, Xiaoyun Nicole Li, Wei Zhou, Adriane M Zernhelt, Joy Lis, Scot Ebbinghaus, S Peter Kang, Adil Daud, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial The Lancet Oncology. ,vol. 16, pp. 908- 918 ,(2015) , 10.1016/S1470-2045(15)00083-2